A U.S. executive order has elevated ibogaine as a priority area for research and treatment, and a Canadian company is moving to build the regulated supply that such a policy shift would require. According to a report by Stock Titan, Optimi Health is expanding its Good Manufacturing Practice production of ibogaine in Canada, positioning itself to serve a growing market if U.S. policy opens further.
Ibogaine is a psychoactive compound derived from the root bark of a plant found in Central Africa. It has been used for decades in some countries to treat opioid addiction, and more recently it has attracted attention from researchers and veterans groups for its potential to address treatment-resistant depression and post-traumatic stress disorder. It remains a Schedule I controlled substance in the United States, meaning it is currently illegal under federal law.
The executive order cited in the Stock Titan report signals that the federal government is interested in moving ibogaine toward clinical availability, particularly for veterans. Studies conducted in other countries have shown promising results for ibogaine in treating opioid use disorder, with some patients reporting significant reductions in cravings after a single treatment session. Researchers have also noted that ibogaine can have serious cardiac side effects, which has contributed to regulatory caution.
Optimi Health's expansion of GMP-certified production is significant because pharmaceutical-grade supply is a prerequisite for clinical trials and eventual regulatory approval. If ibogaine is to move through the U.S. drug approval process, manufacturers will need to demonstrate that they can produce a consistent, contaminant-free product. Building that infrastructure now puts Optimi in a position to supply future trials.
The intersection of federal prioritization and commercial supply development reflects a pattern seen with other psychedelic compounds in recent years. Psilocybin and MDMA have both moved through the research pipeline with a mix of private investment and shifting regulatory attitudes. Ibogaine appears to be following a similar path, with veteran advocacy groups playing a notable role in pushing for access.
Whether the U.S. eventually reschedules ibogaine or creates a pathway for clinical use remains an open question. The executive order establishes intent, but regulatory change involves multiple federal agencies and a review process that takes time. Optimi Health's Canadian operations allow the company to produce and supply the compound legally under Canadian regulations while the U.S. process continues.
